Introduction to Pulse Biosciences at NAST Annual Meeting
Pulse Biosciences, Inc., known for its pioneering Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, will spotlight its innovations at the upcoming North American Society for Interventional Thyroidology Annual Meeting. The event takes place from January 31 to February 1, 2025, in Washington D.C., featuring the company’s nascent approach to benign thyroid nodule treatment.
Showcasing Advanced Technology
According to Paul LaViolette, Co-Chairman and CEO of Pulse Biosciences, their nsPFA technology is designed to be safe and effective, minimizing scarring and preserving vital anatomical structures during soft tissue ablation. LaViolette expressed gratitude to the clinicians exploring this innovative application, emphasizing the potential benefits in future clinical studies for symptomatic benign thyroid nodules.
Highlighted Scientific Programming
The meeting will feature two key presentations: Dr. Camila Mancera will discuss early clinical experiences with nsPFA for benign thyroid nodules on January 31, while Dr. Stefano Spiezia will present key techniques in a video session on February 1. This programming underscores the importance of advancing techniques in thyroid treatment.
Company Commitment and Vision
Pulse Biosciences, based in Miami, Florida, strives to enhance patient quality of life through its unique bioelectric medicine solutions. The CellFX® nsPFA™ technology delivers precise nanosecond pulses that non-thermally clear targeted cells without damaging surrounding tissue, aiming for significant advances in various healthcare sectors.
Forward-Looking Statements
The company’s announcement includes forward-looking statements regarding their nsPFA technology’s effectiveness and ongoing clinical efforts. These insights reflect the company’s optimism while acknowledging the inherent uncertainties in medical technology development. Investors are urged to consider the factors that might influence actual outcomes, as outlined in Pulse Biosciences’ SEC filings.
According to Pulse Biosciences, its nsPFA technology will be highlighted at the 2025 NAST Annual Meeting. Key presentations will feature data on early clinical experiences and techniques for treating benign thyroid nodules. The company aims to enhance patient care through its innovative bioelectric solutions, focusing on minimal scarring and preserving anatomical structures.
Pulse Biosciences is set to showcase its innovative nsPFA technology at the 2025 NAST Annual Meeting, highlighting its potential benefits for benign thyroid nodule treatment. As the company advances its efforts, the presentations reflect a commitment to improving patient outcomes in healthcare. LaViolette’s remarks bolster excitement for future clinical studies supporting this novel technology.
Original Source: www.biospace.com
